Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation study of continuous intravenous PPMX-T003 in aggressive NK-cell leukemia
jRCT2061230008Phase 2Recruiting
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PPMX-T003 in aggressive NK-cell leukemia (ANKL). Primary endpoint: Tolerability and safety during the first course. Started Sep 2023; status: recruiting.
02
Drugs
PPMX-T003
03
Conditions
aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on jRCT2061230008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230008.